{
  "docId": "019de075-1597-7518-8ef8-7c76bda0fb5f",
  "docSlug": "a75249d5a456b06509b9b61a9aec1423",
  "documentTitle": "argenx SE | Results Presentation Deck | 15 slides",
  "authorId": "argenx-se",
  "authorName": "argenx",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 15,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "thesis_headline",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a chevron-based process flow to illustrate the benefits of the product.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1597-7518-8ef8-7c76bda0fb5f/8",
  "deckHref": "/decks/019de075-1597-7518-8ef8-7c76bda0fb5f",
  "deckJsonHref": "/decks/019de075-1597-7518-8ef8-7c76bda0fb5f.json",
  "deckAnchorHref": "/decks/019de075-1597-7518-8ef8-7c76bda0fb5f#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.94,
        "x": 0.03,
        "y": 0.043
      },
      "kind": "diagram",
      "text": "Flexibility and Choice for Patients, Broad HCP Use and Adoption, Best-in-Class Patient Support, Simplicity of Access",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "753d61ea-ead7-42f7-bf7c-861466acfdc1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.23,
        "x": 0.55,
        "y": 0.073
      },
      "kind": "image",
      "text": "VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL vial",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "010aadbd-1596-4000-9094-ec9885510cd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.22,
        "y": 0.073
      },
      "kind": "image",
      "text": "VYVGART (efgartigimod alfa-fcab) Injection for Intravenous Use 400 mg/20 mL vial",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba766f71-0b1c-4525-9c57-cafcdb9c670c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.76,
        "x": 0.12,
        "y": 0.19
      },
      "kind": "title",
      "text": "VYVGART makes treatment simple",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe6deea8-2a0c-4749-9dff-21362fa29ed0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.64,
        "x": 0.18,
        "y": 0.13
      },
      "kind": "title",
      "text": "Chronic autoimmune diseases are complicated",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c595feb-c192-4299-a7b0-688a27637322",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 8,
      "beatId": "2087f5d0-e61d-41b0-9c32-06fc61c714fc",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Thesis Headline",
      "beatSlug": null,
      "evidence": "VYVGART makes treatment simple",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}